Back to discover
Disease
Sarcoidosis
Late-stage therapeutic developmentEmerging researchRising momentum
3
Publications
19
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis.
Research2024-01-02The Journal of clinical investigation
Research2023-06-25International journal of cardiology
ERS clinical practice guidelines on treatment of sarcoidosis.
Research2021-12-16The European respiratory journal
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial
- Q1 2027Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled Trial
- Q3 2027A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a 12-week Administration of OATD-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis (the KITE Study)
- Q3 2029Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis: Multicenter, Prospective, Placebo-controlled, Randomized Trial
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20262026-07-10
Major trial resultsHigh impact
Results posted2026-04-17
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-07-10Cardiac Sarcoidosis Multi-Center Randomized Controlled TrialResults expected Q4 2026
- 2026-04-24Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled TrialResults expected Q1 2027
- 2025-12-12A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a 12-week Administration of OATD-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis (the KITE Study)Results expected Q3 2027
- 2025-09-15Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis: Multicenter, Prospective, Placebo-controlled, Randomized TrialResults expected Q3 2029
Recently completed
- 2026-02-01Vitamin D Homeostasis in SarcoidosisPrimary completion
Activity timeline6
- 2026-07-10ClinicalCardiac Sarcoidosis Multi-Center Randomized Controlled TrialResults expected Q4 2026
- 2026-04-24ClinicalEvaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled TrialResults expected Q1 2027
- 2026-04-17ClinicalClinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar GelResults posted
- 2026-02-01ClinicalVitamin D Homeostasis in SarcoidosisPrimary completion
- 2025-12-12ClinicalA Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of a 12-week Administration of OATD-01, an Oral Inhibitor of Chitinase-1 (CHIT1), for the Treatment of Active Pulmonary Sarcoidosis (the KITE Study)Results expected Q3 2027
- 2025-09-15ClinicalHydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis: Multicenter, Prospective, Placebo-controlled, Randomized TrialResults expected Q3 2029
Clinical trials
The current development programme across all trial phases.
Clinical programme
19
6
14
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20212024
Most influential
Major themes5
- Sarcoidosis3
- Mycobacterium tuberculosis1
- Myocarditis1
- Quality of Life1
- Tuberculosis1
Leading journals3
- International journal of cardiology1
- The European respiratory journal1
- The Journal of clinical investigation1
Leading researchers8
- Antoniou K1
- Baughman RP1
- Bergh N1
- Björkenstam M1
- Bobbio E1
- Bollano E1
- Bonella F1
- Culver DA1
Affiliations (unnormalised)6
- Albany Medical College1
- Center for Interstitial and Rare Lung Diseases1
- Cleveland Clinic1
- Department of Clinical Pathology1
- Department of Clinical Physiology1
- Foundation for Sarcoidosis Research1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.